Trevena Inc. (Nasdaq: TRVN) reported positive results from two Phase 3 studies of the opioid painkiller oliceridine but the Food and Drug Administration requires an additional Phase 3 study. Shares of the biopharmaceutical plunged $2.86 to close at $4.27.
Trevena must conduct additional study
February 21, 2017 at 16:59 PM EST
